Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Osimertinib (Tagrisso) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (first line) 
(Pending Submission as of April 18, 2018)

Regorafenib (Stivarga) for Unresectable Hepatocellular Carcinoma
(Final Recommendation Issued as of April 18, 2018)

Olaratumab (Lartruvo) for Advanced Soft Tissue Sarcoma
(Final Recommendation Issued as of April 18, 2018)

Ribociclib (Kisqali) for Advanced or Metastatic Breast Cancer
(Final Recommendation Issued as of April 18, 2018)

Apalutamide (Brand Name: TBD) for Castrate Resistant Prostate Cancer
(Open for Input on Submission until April 30, 2018)

Alectinib (Alecensaro) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (second line)  
(Notification to Implement Issued as of April 16, 2018)

Panitumumab (Vectibix) for Left Sided Metastatic Colorectal Cancer 
(Notification to Implement Issued as of April 16, 2018)

Nivolumab (Opdivo) for Advanced or Metastatic Hepatocellular Carcinoma
(Pending Submission as of April 10, 2018)

Pertuzumab-Trastuzumab (Perjeta-Herceptin) Combo Pack for Early Breast Cancer 
(Open for Input on Submission until April 23, 2018)

Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy) for Renal Cell Carcinoma
(Pending Submission as of March 28, 2018)

Cetuximab (Erbitux) for Left Sided Metastatic Colorectal Carcinoma 
(Pending Submission as of December 13, 2017)

 

Find a Drug Review